BIO-TECHNE Corp — Director's Dealing 2021

Jan 20, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2021-01-15

Reporting Person: Kummeth Charles R. (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-15	Common Stock	S	20000	$344	Disposed	146269	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	100	Indirect
Common Stock	100	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options (Right to Buy)	$94.35	2021-08-12	Common Stock (66849)	66849	Direct
Stock Options (Right to Buy)	$108.49	2022-08-07	Common Stock (95346)	95346	Direct
Stock Options (Right to Buy)	$108.49	2022-08-07	Common Stock (79517)	79517	Direct
Stock Options (Right to Buy)	$106.59	2023-08-18	Common Stock (154169)	154169	Direct
Stock Options (Right to Buy)	$106.59	2023-08-18	Common Stock (102779)	102779	Direct
Stock Options (Right to Buy)	$125.05	2024-08-09	Common Stock (117342)	117342	Direct
Stock Options (Right to Buy)	$125.05	2024-08-09	Common Stock (78228)	78228	Direct
Restricted Stock Units	$		Common Stock (16918)	16918	Direct
Stock Options (Right to Buy)	$177.32	2025-08-08	Common Stock (90334)	90334	Direct
Stock Options (Right to Buy)	$177.32	2025-08-08	Common Stock (60222)	60222	Direct
Restricted Stock Units	$		Common Stock (16937)	16937	Direct
Stock Options (Right to Buy)	$190.41	2026-08-07	Common Stock (85725)	85725	Direct
Stock Options (Right to Buy)	$190.41	2026-08-07	Common Stock (57150)	57150	Direct
Restricted Stock Units	$		Common Stock (12879)	12879	Direct
Stock Options (Right to Buy)	$267.87	2027-08-05	Common Stock (57442)	57442	Direct
Stock Options (Right to Buy)	$267.87	2027-08-05	Common Stock (38295)	38295	Direct
Stock Options (Right to Buy)	$267.87	2027-08-05	Common Stock (16650.0)	16650.0	Direct
Stock Options (Right to Buy)	$267.87	2027-08-05	Common Stock (16650)	16650	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2020.

F2: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023.

F3: Fully exercisable.

F4: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

F5: Options to purchase 19,557 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and 8/9/2021.

F6: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F7: Options to purchase 15,056 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 15,055 shares vest on each of 8/8/2021 and 8/8/2022.

F8: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F9: Options to purchase 14,288 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 14,287 shares vest on each of 8/7/2022 and 8/7/2023.

F10: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F11: Options to purchase 9,573 shares vest on 8/5/21 and options to purchase 9,574 shares vest on each of 8/5/22, 8/5/23 and 8/5/24.

F12: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.

F13: Options to purchase 5,550 shares vest on each of 8/5/21, 8/5/22 and 8/5/23.